Natrise (Tolvaptan)15mg – 4 tablet

$20.25

Each Natrise contains 15 mg Tolvaptan 4 tablets. Natrise is used to treat hyponatremia (low levels of sodium in your blood)

ATC Classification: C03XA01
Active Ingrediant: Tolvaptan
Generic Name: Natrise
Manufacturer: Sun Pharma
Strength: 15mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 4 TABLET

Examples of Packages sent

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout

Placeholder
Natrise (Tolvaptan)15mg – 4 tablet
$20.25

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Storage/Stability

Jynarque: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Samsca: Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

 

Adverse Reactions

>10%:

Central nervous system: Fatigue (14%), dizziness (11%)

Endocrine & metabolic: Increased thirst (12% to 64%)

Gastrointestinal: Nausea (21%), xerostomia (7% to 16%), diarrhea (13%)

Renal: Polyuria (including pollakiuria, 4% to 70%)

1% to 10%:

Cardiovascular: Palpitations (4%), cerebrovascular accident (<2%), deep vein thrombosis (<2%), intracardiac thrombus (<2%), pulmonary embolism (<2%), ventricular fibrillation (<2%)

Dermatologic: Xeroderma (5%), skin rash (4%)

Endocrine & metabolic: Increased serum sodium (2% to 7%), hyperglycemia (6%), hyperuricemia (4%), hypernatremia (≤4%), dehydration (2% to 3%), hypovolemia (2%), diabetic ketoacidosis (<2%)

Gastrointestinal: Gastrointestinal hemorrhage (cirrhosis patients, 10%), dyspepsia (8%), constipation (7%), decreased appetite (7%), abdominal distention (5%), anorexia (4%), ischemic colitis (<2%)

Genitourinary: Urethral bleeding (<2%), vaginal hemorrhage (<2%)

Hematologic & oncologic: Disseminated intravascular coagulation (<2%), prolonged prothrombin time (<2%)

Hepatic: Increased serum alanine aminotransferase (5%)

Neuromuscular & skeletal: Asthenia (9%), rhabdomyolysis (<2%)

Respiratory: Respiratory failure (<2%)

Miscellaneous: Fever (4%)

<1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, hepatic failure, hepatotoxicity, hyperkalemia, hypersensitivity reaction, increased serum bilirubin, osmotic demyelination syndrome, skin rash

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , ,

Strength

Dosage Type

Packaging Type